Cancer cells may harbor an exploitable weakness when they lose a critical mitochondrial enzyme, creating opportunities for precision treatments that target DNA repair pathways. This finding challenges the traditional view that mitochondrial metabolism and nuclear DNA stability operate independently.
When cancer cells lose the enzyme LIPT1, which normally helps process nutrients through the mitochondrial energy cycle, they accumulate a metabolite called 2-hydroxyglutarate. This compound disrupts the normal packaging of DNA by inhibiting enzymes that remove methyl groups from histones, leading to overly compressed chromatin structures. As DNA replication machinery encounters these tightly packed regions, it stalls and requires emergency bypass mechanisms. The cell deploys PrimPol, a specialized enzyme that restarts DNA synthesis by jumping over problematic areas, but this rescue operation leaves behind single-stranded DNA gaps that demand PARP1 enzyme activity for proper repair.
This metabolic cascade reveals why certain cancers become exquisitely sensitive to PARP inhibitor drugs, which are already approved for treating BRCA-mutated breast and ovarian cancers. The research suggests that LIPT1-deficient tumors could represent a new category of cancers vulnerable to these targeted therapies. However, the work was conducted primarily in cell culture models, and the prevalence of LIPT1 deficiency across different cancer types remains unclear. The findings nonetheless provide a compelling example of how disrupted cellular energy production can cascade into genome instability, potentially expanding the population of patients who might benefit from precision DNA repair-targeting treatments.